Volume 27, Number 7—July 2021
CME ACTIVITY - Research
Non–C. difficile Clostridioides Bacteremia in Intensive Care Patients, France
Guillaume Morel
, Guillaume Mulier, Etienne Ghrenassia, Moustafa Abdel Nabey, Yacine Tandjaoui, Achille Kouatchet, Laura Platon, Frédéric Pène, Anne-Sophie Moreau, Amelie Seguin, Damien Contou, Romain Sonneville, David Rousset, Muriel Picard, Guillaume Dumas, Djamel Mokart, Bruno Megarbane, Guillaume Voiriot, Isabelle Oddou, Elie Azoulay, Lucie Biard, and Lara Zafrani
, Guillaume Mulier, Etienne Ghrenassia, Moustafa Abdel Nabey, Yacine Tandjaoui, Achille Kouatchet, Laura Platon, Frédéric Pène, Anne-Sophie Moreau, Amelie Seguin, Damien Contou, Romain Sonneville, David Rousset, Muriel Picard, Guillaume Dumas, Djamel Mokart, Bruno Megarbane, Guillaume Voiriot, Isabelle Oddou, Elie Azoulay, Lucie Biard, and Lara Zafrani
Table 2
Clinical and biologic characteristics of patients with Closteridiodes bacteremia, France*
| Characteristic | All patients, n = 135 |
Survived, n = 65 |
Died in ICU, n = 70 |
|||||
|---|---|---|---|---|---|---|---|---|
| No. | Result | No. | Result | No. | Result | |||
| Temperature |
75 |
37 (36–39) |
30 |
38.5 (37.3–39) |
45 |
37 (35.6–38.7) |
||
| Clinical manifestations associated with bacteremia at ICU admission | ||||||||
| Septic shock | 115 | 85% | 49 | 75% | 66 | 94% | ||
| Digestive symptoms | 84 | 62% | 42 | 65% | 42 | 60% | ||
| Acute respiratory failure | 41 | 30% | 15 | 23% | 26 | 37% | ||
| Coma | 38 | 28% | 6 | 9% | 32 | 46% | ||
| Cardiac arrest | 26 | 19% | 2 | 3% | 24 | 34% | ||
| Myonecrosis |
21 |
16% |
11 |
17% |
10 |
14% |
||
| Prognostic scores at ICU admission | ||||||||
| Charlson score | 135 | 5 (3–6) | 65 | 5 (2–7) | 70 | 4.5 (3–6) | ||
| SAPS2 score | 106 | 63 (44–88) | 47 | 45 (33–57) | 59 | 82 (63–97) | ||
| SOFA score |
105 |
10 (7–14) |
47 |
8 (5–10) |
58 |
12 (9–15) |
||
| Organ support in ICU | ||||||||
| Vasopressors, n = 132 | 108 | 82% | 42 | 66% | 66 | 97% | ||
| Mechanical ventilation, n = 133 | 105 | 79% | 41 | 63% | 64 | 94% | ||
| Renal-replacement therapy, n = 131 |
44 |
34% |
17 |
26% |
27 |
41% |
||
| Biologic parameters at ICU admission | ||||||||
| Leukocytes, × 109/L | 97 | 9.5 (2.8–17.8) | 49 | 9.5 (6.1–20.2) | 48 | 9.3 (1.6–16.0) | ||
| Platelets, × 109/L | 93 | 141 (76–214) | 45 | 143 (73–217) | 48 | 138 (84–206) | ||
| Hemoglobin, g/dL | 92 | 10.3 (7.8–12.2) | 45 | 10.2 (8.8–12.2) | 47 | 10.3 (7.0–11.9) | ||
| Hemolysis, n = 130 |
22 |
17% |
6 |
9% |
16 |
24% |
||
| Acute renal failure, n = 107 | ||||||||
| KDIGO classification 1 | 14 | 13% | 10 | 20% | 4 | 7% | ||
| KDIGO classification 2 | 34 | 32% | 19 | 38% | 15 | 26% | ||
| KDIGO classification 3 |
59 |
55% |
21 |
42% |
38 |
67% |
||
| Other | ||||||||
| Aspartate aminotransferase, UI/L | 80 | 92 (41–269) | 38 | 71 (41–172) | 42 | 134 (44–346) | ||
| Alanine aminotransferase, UI/L | 81 | 54 (25–142) | 39 | 47 (21–125) | 42 | 69 (27–152) | ||
| Bilirubin, µmol/L | 69 | 22 (10–45) | 34 | 27 (10.3–52.3) | 35 | 19.5 (10.5–35.7) | ||
| Lactatemia, mmol/L | 93 | 5.3 (2.3–8.8) | 40 | 3.2 (1.5–5.2) | 53 | 8 (4.9–12) | ||
| pH | 93 | 7.29 (7.13–7.4) | 40 | 7.38 (7.32–7.43) | 53 | 7.18 (7.05–7.31) | ||
*Results are given as percentages or median (interquartile range). ICU, intensive care unit; KDIGO, Kidney Disease: Improving Global Outcomes (https://kdigo.org); SAPS2, simplified acute physiology score (SAPS2); SOFA, sequential organ failure assessment.
Page created: May 27, 2021
Page updated: June 18, 2021
Page reviewed: June 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.